Answers are grounded in this paper and cite their sources.
Genome sequencing of Methanomethylovorans thermophila validates its phylogenetic position, indicating its metabolic capabilities.
The genome of the methanogenic archaeon Methanomethylovorans thermophila L2FAW was sequenced via Illumina shot-gun and Oxford Nanopore sequencing and subsequently hybrid assembled for the phylogenomic placement in the archaeal Genome Taxonomy Database (GTDB). The assembled genome consists of 2.25 Mbp (contigs ≥ 500 bp) with a G+C content of 37.97%. The quality of the genome is good, which is already apparent from the low L50 (= 1) and L90 (= 2) metrics. Our assembled genome was highly similar to the metagenome assembled genome Methanomethylovorans sp014361205 (GCA_014361205.1_ASM1436120v1_genomic) with an average nucleotide identity (ANI) of 99.9%. Visualization of the amino acid annotation with KEGG Mapper Reconstruction Result revealed that M. thermophila L2FAW harbors all the enzymes necessary for acetoclastic and hydrogenotrophic methanogenesis. Additionally, the predicted metabolic model showed that formate is a potential substrate for M. thermophila L2FAW. Nonetheless, no metabolic activity could be observed in lab tests on acetate, H2-CO2 (80:20 vol/vol, 2000 mbar), and a mixture of H2-CO2 (80:20 vol/vol, 2000 mbar) and formate.
No takes yet. Share an insight, caveat, or question.
Wunderer et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: